

Other version: https://academic.oup.com/jcem/article/103/8/2949/5001732
![]() |
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis |
|
Authors | ![]() | |
Published in | Journal of Clinical Endocrinology and Metabolism. 2018, vol. 103, no. 8, p. 2949-2957 | |
Identifiers | ||
Full text |
![]() ![]() Other version: https://academic.oup.com/jcem/article/103/8/2949/5001732 |
|
Structures | ||
Research group | Génétique des ostéoporoses (544) | |
Citation (ISO format) | BONE, Henry G et al. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. In: Journal of Clinical Endocrinology and Metabolism, 2018, vol. 103, n° 8, p. 2949-2957. doi: 10.1210/jc.2018-00163 https://archive-ouverte.unige.ch/unige:111093 |